Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...

Nicole Verdun, MD, super office director of the FDA’s Office of Therapeutic Products (OTP) and her deputy Rachael Anatol, PhD ...

Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

The Alliance for Regeneration Medicine (ARM), a trade group that represents more than 400 members companies across 25 ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

When Americans imagine the future, it always has a lot to do with flying cars, robot housekeepers, and just about anything ...

Capricor stock drops as FDA cancels advisory meeting on Duchenne therapy; leadership changes and regulatory tensions fuel uncertainty.

In the wake of Marks' exit, FDA commissioner Marty Makary, M.D., named Vinay Prasad, M.D., to head up CBER. In addition to that title, Prasad recently added the title of "chief medical and science ...

Curay, who stepped into the role as the agency’s top drug regular in January, is departing in July, according to an email ...

This leadership vacuum follows another significant departure at the FDA. Peter Marks, former head of the Center for Biologics Evaluation and Research who worked closely with Verdun on establishing new ...